Pharmascience Welcomes Canadian Ruling On Nitrosamines
Class Action Related To Presence Of NDMA In Ranitidine Dismissed
Pharmascience was among the firms that were named in a class action lawsuit in Canada over the presence of nitrosamine NDMA in ranitidine. Now, the company has welcomed a summary judgement decision by the Supreme Court of British Columbia to dismiss the claims.
You may also be interested in...
Samsung Bioepis has received an EMA nod for its Sandoz-partnered Stelara biosimilar under the name Pyzchiva. Meanwhile, the agency’s CHMP also recommended granting centralized marketing authorizations for two Accord generics.
Teva’s innovative and generic interests can not only co-exist but are complementary, CEO Richard Francis has set out, in response to questions over whether the Israeli giant would consider splitting its businesses to focus more on branded drugs.
Proposed French legislation that would address shortages by strengthening obligations to hold security stocks – with the threat of sanctions for suppliers – would be counter-productive, local generics industry association Gemme has warned.